Efficient intracellular therapeutic antibodies – VectorY platform
VectorY’s platform delivers long-lasting CNS treatments through antibody, AAV, and advanced manufacturing technologies.
vectorytx.comCrawled Nov 11, 2026
VectorY’s platform delivers long-lasting CNS treatments through antibody, AAV, and advanced manufacturing technologies.
VectorY is developing a one-time treatment to alter the progression of amyotrophic lateral sclerosis (ALS).
VectorY is working on a one-time treatment for Huntington’s disease, a neurodegenerative condition with significant unmet medical needs.
The page lists publications and presentations related to the company’s programs and platform technology.
The page provides updates on VectorY’s latest press releases and scientific progress.
VectorY Therapeutics invites interns to join its biotech company.
The page describes career opportunities at VectorY Therapeutics.
Jessica Atkinson was appointed as Chief Business Officer of VectorY Therapeutics in May 2025. Ms. Atkinson brings over 20 years of experience in business development and commercialization, having held leadership roles at ImmuneID, Glympse Bio, and Foundation Medicine, and worked in the U.S. commercial organization at Merck & Co.
Jim Scibetta joined VectorY Therapeutics as CEO in 2024. Mr. Scibetta brings more than 20 years of executive leadership experience, building earlier stage companies developing novel therapeutics for high unmet medical needs into more mature biotechnology companies driving high value exits.
Olga Uspenskaya-Cadoz joined VectorY Therapeutics as Chief Medical Officer in April 2025, bringing over 20 years of expertise in neurology, gene therapy, and clinical development. She oversees clinical and regulatory strategy for the company’s vectorized antibody therapies targeting neurodegenerative diseases.
Founder, Chief Operating Officer and Site Head
Adam serves as Chair of the Board of Directors at Seamless Therapeutics and Ambagon Therapeutics, and as a Director for other biotechnology companies. He previously founded Aliada Therapeutics, Athenen Therapeutics (merged with Eliem Therapeutics), and Sionna Therapeutics, and led Rodin Therapeutics until its 2019 acquisition.
The company’s team specializes in antibody and AAV vector development to advance therapies for patients.
VectorY Therapeutics operates offices and labs at the Amsterdam Science Park, located in the Dutch biotech ecosystem.
A biotech company dedicated to developing transformative medicines for people with neurodegenerative diseases using cutting-edge science and technologies.
A biotech company dedicated to developing transformative medicines for people with neurodegenerative diseases using cutting-edge science and technologies.